SCHEMBL3018162

SCHEMBL3018162

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GBA1 P04062 2/20 0.41
HSD11B1 P28845 1/20 0.40
ABL1 P00519 1/20 0.40
BCR P11274 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CNR1 P21554 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010490 0.93 POLB (0.44) ALDH1A1KDM4EHTTNPSR1SMN1; SMN2
SCHEMBL3012502 0.92 ALDH1A1 (0.47) ALDH1A1KDM4EHTTNPSR1SMN1; SMN2
SCHEMBL3019973 0.92 THRB (0.47) ALDH1A1KDM4ENPSR1SMN1; SMN2L3MBTL1
SCHEMBL3016050 0.91 ALDH1A1 (0.46) ALDH1A1KDM4EHTTNPSR1L3MBTL1
SCHEMBL3010733 0.91 ALDH1A1 (0.48) ALDH1A1KDM4EHTTNPSR1SMN1; SMN2
SCHEMBL3006852 0.91 ALDH1A1 (0.48) ALDH1A1KDM4EHTTNPSR1SMN1; SMN2
SCHEMBL3013725 0.91 ALDH1A1 (0.40) ALDH1A1KDM4EHTTNPSR1SMN1; SMN2
SCHEMBL3016473 0.90 CNR1 (0.43) ALDH1A1KDM4ESMN1; SMN2L3MBTL1GBA1
SCHEMBL3015254 0.90 ALDH1A1 (0.42) ALDH1A1KDM4EHTTNPSR1SMN1; SMN2
SCHEMBL3013183 0.90 CNR1 (0.51) ALDH1A1KDM4EHTTSMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885KDM4E 4398/4885HTT 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.